• This is a political forum that is non-biased/non-partisan and treats every person's position on topics equally. This debate forum is not aligned to any political party. In today's politics, many ideas are split between and even within all the political parties. Often we find ourselves agreeing on one platform but some topics break our mold. We are here to discuss them in a civil political debate. If this is your first visit to our political forums, be sure to check out the RULES. Registering for debate politics is necessary before posting. Register today to participate - it's free!

Once free, drug for rare disease now being sold for $375K a year


Supporting Member
DP Veteran
Monthly Donator
Dec 3, 2017
Reaction score
Political Leaning

Thanks to a law designed to encourage drug development for rare diseases, Catalyst Pharmaceuticals can now sell the treatment exclusively for seven years -- and has set the price for it at $375,000 on average, when it used to be given to patients for free by a smaller drug company.


Bernie Sanders Calls out Catalyst Pharmaceuticals Over Price of LEMS Drug Firdapse

U.S. Sen. Bernie Sanders has a history of taking on the pharmaceutical industry and prices for prescription medicines that he sees as unjust. This week, the Vermont senator has found a new target, Florida-based Catalyst Pharmaceuticals.

On Monday, Sanders sent a letter to Patrick J. McEnany, chairman and chief executive officer of Catalyst Pharmaceuticals, in regards to the $375,000 price tag for its recently-approved drug, Firdapse (amifampridine). In November 2018, after a previous rejection, Catalyst won approval from the U.S. Food and Drug Administration for the oral drug, as a first-ever approved treatment for Lambert-Eaton myasthenic syndrome (LEMS).
How can Joe Downthestreet who has LEMS come up with $375K? This law on drugs for rare diseases should be looked at by regulators.
Top Bottom